Idarubicin in advanced breast cancer: a phase II study.
Twenty-nine patients with metastatic breast cancer were treated orally with idarubicin (15 mg/m2 X 3 days every 3-4 weeks). Objective response was seen in 31% of all patients. Toxicity was acceptable. There should be further clinical trials of new anthracycline antibiotic.
Lionetto
R
R
Pronzato
P
P
Conte
P F
PF
Sertoli
M R
MR
Amoroso
D
D
Rosso
R
R
D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D015255:Idarubicin; D008875:Middle Aged; D009362:Neoplasm Metastasis
D015255:Idarubicin; D003630:Daunorubicin